Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03016741 · ClinicalTrials.gov registry record · Phase 4
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
A Phase 4 study of Metastatic Prostate Carcinoma and Recurrent Prostate Carcinoma, sponsored by Northwestern University.
- Active
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 5
- Study locations
NCT03016741: Active Phase 4 study of Metastatic Prostate Carcinoma and Recurrent Prostate Carcinoma, sponsored by Northwestern University.
NCT03016741 is a Phase 4 study of Metastatic Prostate Carcinoma and Recurrent Prostate Carcinoma that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 100 participants, below the 130-participant average among 37 other Metastatic Prostate Carcinoma trials with a reported enrollment target (23% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03016741, a Phase 4 study of Metastatic Prostate Carcinoma and Recurrent Prostate Carcinoma, is active but no longer recruiting, sponsored by Northwestern University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 5
- Study locations
Study Summary
This clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide. The investigators use MRI imaging (non-invasive, non-contrast) to see whether there are changes in brain structure or activity related to treatment that may be related to changes in cognitive function. The investigators are also looking for genetic variations that might make patients more or less sensitive to cognitive changes during treatment for prostate cancer.
Primary Outcome
Raw scores on each module of the Cogstate test will be converted to standardized scores (z-scores and T-scores) according to age and/or education-adjusted published normative data per the Cogstate protocol. Linear regressions will be utilized to assess the mean differences between groups at each time point after the baseline while adjusting for baseline scores.
Conditions Studied
Interventions
- DRUG Prednisone
- DRUG Enzalutamide
- DRUG Abiraterone Acetate
- BIOLOGICAL GnRH agonist/antagonist
Study Locations (5)
California
- City of Hope Comprehensive Cancer Center - Los Angeles
Illinois
- Northwestern University - Chicago
Louisiana
- Tulane Cancer Center - New Orleans
Minnesota
- University of Minnesota: Masonic Cancer Center - Minneapolis
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-03-31 |
| Est. Completion | 2029-08 |
| Phase | Phase 4 |
What the registry record for NCT03016741 still lists
NCT03016741 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 130-participant average among 37 other Metastatic Prostate Carcinoma trials with a reported enrollment target (23% lower).
The record links to 5 conditions, with Metastatic Prostate Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Prednisone is the first listed.
NCT03016741 lists 5 locations in 5 states (California, Illinois, Louisiana).
Frequently Asked Questions
What is clinical trial NCT03016741 about?
NCT03016741 is a clinical study titled "Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer". This clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide. The investigators use MRI imaging (non-invasive, non-contrast) to see whether there are changes in brain structure or activity re...
What is the current status of trial NCT03016741?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2017-03-31. Estimated completion is 2029-08.
What conditions does trial NCT03016741 study?
This clinical trial studies the following conditions: Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Castration Resistant Prostatic Cancer, Hormone-refractory Prostate Cancer.
What interventions are being tested in trial NCT03016741?
The interventions under investigation include: Prednisone (DRUG), Enzalutamide (DRUG), Abiraterone Acetate (DRUG), GnRH agonist/antagonist (BIOLOGICAL).
Who is sponsoring clinical trial NCT03016741?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03016741 being conducted?
This trial has 5 study locations across California, Illinois, Louisiana, Minnesota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03016741's enrollment target sits among peer trials
100 11th of 37 higher than 27 of 37 other Metastatic Prostate Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients
RECRUITING · Early Phase 1
-
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
RECRUITING
-
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
RECRUITING · NA
-
Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
RECRUITING · NA
-
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI